Oximetry reveals abnormal oxygen metabolism in exudative AMD

Article

Professor Stef?nsson reveals the results of a comparative study demonstrating that observation of metabolic processes is possible enabling insight into the pathophysiology of disease.

The design of the non-invasive retinal oximeter is based on a fundus camera. It simultaneously captures images of the retina at 600 nm and 570 nm and estimates retinal vessel oxygen saturation, then producing an image in which the degrees of oxygen saturation are indicated by different colours.

To establish whether the retina metabolises oxygen differently in an eye with AMD than in a healthy eye, the Oximetry Group in Reykjavik, including Asbjorg Geirsdottir, Sveinn Hakon Hardarson and professor Einar Stefánsson (University of Iceland, National University Hospital, Reykjavik, Iceland) compared the oximetry images of healthy eyes with those of eyes with exudative AMD.

When oxygen saturation in AMD patients is compared with healthy individuals a statistically significant difference is seen. While the venous oxygen saturation of healthy individuals decreases with age, in AMD patients the opposite pattern is seen.

He continued, "The preliminary results indicate that oxygen metabolism is different in healthy and AMD eyes."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.